TBX1 Functions as a Tumor Suppressor in Thyroid Cancer Through Inhibiting the Activities of the PI3K/AKT and MAPK/ERK Pathways

被引:47
|
作者
Wang, Na [1 ]
Li, Yiqi [1 ]
Wei, Jing [1 ]
Pu, Jun [1 ]
Liu, Rui [4 ]
Yang, Qi [1 ]
Guan, Haixia [5 ]
Shi, Bingyin [1 ,2 ]
Hou, Peng [1 ,2 ]
Ji, Meiju [3 ]
机构
[1] Xi An Jiao Tong Univ, Dept Endocrinol, Affiliated Hosp 1, Xian, Shaanxi, Peoples R China
[2] Xi An Jiao Tong Univ, Key Lab Tumor Precis Med Shaanxi Prov, Affiliated Hosp 1, Xian, Shaanxi, Peoples R China
[3] Xi An Jiao Tong Univ, Ctr Translat Med, Affiliated Hosp 1, Xian, Shaanxi, Peoples R China
[4] Xi An Jiao Tong Univ, Sch Med, Affiliated Hosp 1, Xian, Shaanxi, Peoples R China
[5] China Med Univ, Affiliated Hosp 1, Dept Endocrinol & Metab, Shenyang, Liaoning, Peoples R China
基金
中国国家自然科学基金;
关键词
thyroid cancer; TBX1; epithelial-mesenchymal transition; PI3K; AKT pathway; MAPK; ERK pathway; TRANSCRIPTION FACTOR TBX1; MATRIX METALLOPROTEINASES; GROWTH; REGULATOR; PROMOTES; PROLIFERATION; INACTIVATION; DEGRADATION; STATISTICS; ACTIVATION;
D O I
10.1089/thy.2018.0312
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: TBX1 is a member of the T-box family of transcription factors characterized by a conserved DNA binding domain termed T-box. TBX1 has been reported to be downregulated in mouse skin tumors and is considered a negative regulator of tumor cell growth in mice. However, its role and exact mechanism in human cancers, including thyroid cancer, remain totally unknown. Methods: Quantitative reverse transcription polymerase chain reaction and Western blot assays were performed to evaluate the expression of investigated genes. Methylation-specific polymerase chain reaction and pyrosequencing were used to analyze TBX1 promoter methylation. The biological functions of TBX1 in thyroid cancer cells were determined by a series of in vitro and in vivo experiments. Chromatin immunoprecipitation sequencing and dual-luciferase reporter assays were used to identify its downstream targets. Results: This study demonstrates that TBX1 is frequently downregulated by promoter methylation in both papillary thyroid cancers and thyroid cancer cell lines. Ectopic expression of TBX1 in thyroid cancer cells dramatically inhibits cell viability, colony formation, and tumorigenic potential in nude mice, and induces cell-cycle arrest and apoptosis through modulating a panel of cell-cycle and apoptosis-related genes. In addition, ectopic expression of TBX1 significantly decreases the migration and invasion potential of thyroid cancer cells through inhibiting the process of epithelial-mesenchymal transition and the expression of matrix metalloproteinases. On the other hand, TBX1 knockdown markedly promotes thyroid cancer cell viability and invasiveness. Mechanistically, TBX1 exerts its tumor suppressor function in thyroid cancer cells through inhibiting phosphorylation of AKT at Ser473 and ERK via regulating its downstream targets such as RNF41, PARK2, and PHLPP2. Conclusions: The data show that TBX1 is frequently inactivated by promoter methylation and functions as a potential tumor suppressor in thyroid cancer through inhibiting the activities of the PI3K/AKT and MAPK/ERK signaling pathways.
引用
收藏
页码:378 / 394
页数:17
相关论文
共 50 条
  • [1] ENKUR acts as a tumor suppressor in lung adenocarcinoma cells through PI3K/Akt and MAPK/ERK signaling pathways
    Ma, Qing
    Lu, Yin
    Lin, Jie
    Gu, Ye
    JOURNAL OF CANCER, 2019, 10 (17): : 3975 - 3984
  • [2] Metallothionein 1G functions as a tumor suppressor in thyroid cancer through modulating the PI3K/Akt signaling pathway
    Fu, Jiao
    Lv, Hongjun
    Guan, Haixia
    Ma, Xiaoying
    Ji, Meiju
    He, Nongyue
    Shi, Bingyin
    Hou, Peng
    BMC CANCER, 2013, 13
  • [3] Metallothionein 1G functions as a tumor suppressor in thyroid cancer through modulating the PI3K/Akt signaling pathway
    Jiao Fu
    Hongjun Lv
    Haixia Guan
    Xiaoying Ma
    Meiju Ji
    Nongyue He
    Bingyin Shi
    Peng Hou
    BMC Cancer, 13
  • [4] FGF14 Functions as a Tumor Suppressor through Inhibiting PI3K/AKT/mTOR Pathway in Colorectal Cancer
    Su, Tianhong
    Huang, Linlin
    Zhang, Ning
    Peng, Sui
    Li, Xiaoxing
    Wei, Guangyan
    Zhai, Ertao
    Zeng, Zhirong
    Xu, Lixia
    JOURNAL OF CANCER, 2020, 11 (04): : 819 - 825
  • [5] Synergistic inhibition of thyroid cancer by suppressing MAPK/PI3K/AKT pathways
    Kandil, Emad
    Tsumagari, Koji
    Ma, Jingjing
    Elmageed, Zakaria Y. Abd
    Li, Xinying
    Slakey, Douglas
    Mondal, Debasis
    Abdel-Mageed, Asim B.
    JOURNAL OF SURGICAL RESEARCH, 2013, 184 (02) : 898 - 906
  • [6] Antrocin Sensitizes Prostate Cancer Cells to Radiotherapy through Inhibiting PI3K/AKT and MAPK Signaling Pathways
    Chen, Yu-An
    Tzeng, David T. W.
    Huang, Yi-Ping
    Lin, Chun-Jung
    Lo, U-Ging
    Wu, Chia-Lin
    Lin, Ho
    Hsieh, Jer-Tsong
    Tang, Chih-Hsin
    Lai, Chih-Ho
    CANCERS, 2019, 11 (01):
  • [7] Zinc-finger protein 545 is inactivated due to promoter methylation and functions as a tumor suppressor through the Wnt/β-catenin, PI3K/AKT and MAPK/ERK signaling pathways in colorectal cancer
    Xiang, Shili
    Xiang, Tingxiu
    Xiao, Qian
    Li, Yunhai
    Shao, Bianfei
    Luo, Tao
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2017, 51 (03) : 801 - 811
  • [8] Effects of evodiamine on PI3K/Akt and MAPK/ERK signaling pathways in pancreatic cancer cells
    Hong, Zhong
    Wang, Zhaohong
    Zhou, Bin
    Wang, Jisheng
    Tong, Hongfei
    Liao, Yi
    Zheng, Peng
    Jamshed, Muhammad Babar
    Zhang, Qiyu
    Chen, Hui
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2020, 56 (03) : 783 - 793
  • [9] Targeting MAPK (Ras/ERK) and PI3K/Akt pathways in pituitary tumorigenesis
    Cakir, Mehtap
    Grossman, Ashley B.
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2009, 13 (09) : 1121 - 1134
  • [10] Apatinib inhibits pancreatic cancer growth, migration and invasion through the PI3K/AKT and ERK1/2/MAPK pathways
    Hu, Yuan
    Jing, Jiayu
    Shi, Yu
    Zhang, Pengchuang
    Dong, Danfeng
    Wu, Yinying
    Dong, Xuyuan
    Li, Enxiao
    Fan, Yangwei
    TRANSLATIONAL CANCER RESEARCH, 2021, 10 (07) : 3306 - 3316